Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

October 20, 2009

Primary Completion Date

March 21, 2011

Study Completion Date

March 21, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

GSK2340274A

Two intramuscular injections

BIOLOGICAL

GSK2340273A

Two intramuscular injections

Trial Locations (30)

37660

GSK Investigational Site, Kingsport

40004

GSK Investigational Site, Bardstown

44121

GSK Investigational Site, Cleveland

55108

GSK Investigational Site, Saint Paul

67005

GSK Investigational Site, Arkansas City

67205

GSK Investigational Site, Wichita

68134

GSK Investigational Site, Omaha

70006

GSK Investigational Site, Metairie

72034

GSK Investigational Site, Conway

72202

GSK Investigational Site, Little Rock

76135

GSK Investigational Site, Fort Worth

76904

GSK Investigational Site, San Angelo

78705

GSK Investigational Site, Austin

84057

GSK Investigational Site, Orem

84095

GSK Investigational Site, South Jordan

94102

GSK Investigational Site, San Francisco

95816

GSK Investigational Site, Sacramento

V3K 3P4

GSK Investigational Site, Coquitlam

R3A 1M3

GSK Investigational Site, Winnipeg

A1A 3R5

GSK Investigational Site, St. John's

B3K 6R8

GSK Investigational Site, Halifax

L6T 0G1

GSK Investigational Site, Brampton

P3E 1H5

GSK Investigational Site, Greater Sudbury

L8L 5G8

GSK Investigational Site, Hamilton

L3Y 5G8

GSK Investigational Site, Newmarket

M5G 1N8

GSK Investigational Site, Toronto

M9V 4B4

GSK Investigational Site, Toronto

H3T 1C5

GSK Investigational Site, Montreal

G1V 4T3

GSK Investigational Site, Québec

J1H 1Z1

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00976820 - Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age | Biotech Hunter | Biotech Hunter